Literature DB >> 20022685

IVF outcome in women with PCOS, PCO and normal ovarian morphology.

Alexander Swanton1, Lisa Storey, Enda McVeigh, Tim Child.   

Abstract

OBJECTIVE: To examine the outcome of IVF in women who have normal ovaries, ovulatory PCO or PCOS. STUDY
DESIGN: Analysis of a prospectively collected database in an assisted conception unit in a university teaching hospital including 290 women <37 years of age undergoing their first IVF cycle. The main outcome measure was severe OHSS requiring hospitalization.
RESULTS: Severe OHSS rates were significantly higher in women with PCO (12.6%) and PCOS (15.4%) compared to those with normal ovaries (2.7%). Coasting was used significantly more often. Live birth rates per cycle started are similar among women with PCO (38%), PCOS (37%) and normal ovaries (40%).
CONCLUSION: Women with ovaries of polycystic morphology are at increased risk of developing severe OHSS and of requiring avoidance techniques such as coasting, regardless of ovulatory status. However, live birth rates per cycle are similar to women with normal ovaries. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20022685     DOI: 10.1016/j.ejogrb.2009.11.017

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  27 in total

1.  Folate metabolism gene polymorphisms MTHFR C677T and A1298C and risk for preeclampsia: a meta-analysis.

Authors:  Xiaoming Wu; Kunxian Yang; Xiaodan Tang; Yalian Sa; Ruoyu Zhou; Jing Liu; Ying Luo; Wenru Tang
Journal:  J Assist Reprod Genet       Date:  2015-03-11       Impact factor: 3.412

Review 2.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

3.  Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment.

Authors:  Hang Wun Raymond Li; Vivian Chi Yan Lee; Estella Yee Lan Lau; William Shu Biu Yeung; Pak Chung Ho; Ernest Hung Yu Ng
Journal:  J Assist Reprod Genet       Date:  2013-12-14       Impact factor: 3.412

4.  Prolonged gonadotropin stimulation for assisted reproductive technology cycles is associated with decreased pregnancy rates for all women except for women with polycystic ovary syndrome.

Authors:  Amanda Ryan; Shunping Wang; Ruben Alvero; Alex J Polotsky
Journal:  J Assist Reprod Genet       Date:  2014-05-28       Impact factor: 3.412

5.  Renaming PCOS--a two-state solution.

Authors:  Andrea Dunaif; Bart C J M Fauser
Journal:  J Clin Endocrinol Metab       Date:  2013-09-05       Impact factor: 5.958

6.  The clinical ramifications of polycystic ovarian morphology in oocyte donors.

Authors:  M Cho; G Ambartsumyan; H Danzer; K Brennan; M Surrey
Journal:  J Assist Reprod Genet       Date:  2013-01-05       Impact factor: 3.412

7.  The impact of polycystic ovary syndrome and body mass index on the absorption of recombinant human follicle stimulating hormone.

Authors:  Malinda S Lee; Andrea Lanes; Andrey V Dolinko; Alexandra Bailin; Elizabeth Ginsburg
Journal:  J Assist Reprod Genet       Date:  2020-07-04       Impact factor: 3.412

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

9.  GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.

Authors:  Kathleen E O'Neill; Suneeta Senapati; Ivy Maina; Clarisa Gracia; Anuja Dokras
Journal:  J Assist Reprod Genet       Date:  2016-06-27       Impact factor: 3.412

10.  Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS.

Authors:  D Fischer; C Reisenbüchler; S Rösner; J Haussmann; P Wimberger; M Goeckenjan
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-06       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.